Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736900 | 0.92 | HRH3 (0.42) | HRH3KCNH2HRH2HRH1MAOB | |
| SCHEMBL737521 | 0.91 | HRH3 (0.47) | HRH3KCNH2HRH2HRH1MAOB | |
| SCHEMBL736560 | 0.87 | HRH3 (0.47) | HRH3KCNH2HRH2HRH1MAOB | |
| SCHEMBL737583 | 0.85 | HRH3 (0.47) | HRH3KCNH2HRH2HRH1MAOB | |
| SCHEMBL738084 | 0.85 | HRH3 (0.46) | HRH3KCNH2HRH2HRH1MAOB | |
| SCHEMBL737607 | 0.85 | HRH3 (0.54) | HRH3KCNH2HRH2HRH1MAOB | |
| SCHEMBL736128 | 0.84 | HRH3 (0.47) | HRH3KCNH2HRH2HRH1MAOB | |
| SCHEMBL735247 | 0.84 | HRH3 (0.46) | HRH3KCNH2HRH2HRH1MAOB | |
| SCHEMBL738908 | 0.83 | HRH3 (0.51) | HRH3KCNH2HRH2HRH1MAOB | |
| SCHEMBL735211 | 0.83 | HRH3 (0.43) | HRH3KCNH2HRH2HRH1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | claimed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | claimed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | claimed |
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | HRH3 2/4885KCNH2 308/4885HRH2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.